Ultragenyx rises after FDA nod for rare disorder drug
BUZZ-Ultragenyx rises after FDA nod for rare disorder drug ** Shares of drugmaker Ultragenyx Pharmaceutical RARE.O rise 1% to $14.65 premarket, after closing up 12.58% on Thursday
** US Food and Drug Administration late on Thursday approved Ultragenyx's gene therapy, Fayuvi, as the first treatment for children with Sanfilippo syndrome Type A
** Sanfilippo syndrome Type A is an inherited condition that progressively damages the brain and nervous system
** RARE set a US list price of $3.95 million for Fayuvi, launching one of the world's most expensive drugs as a one-time treatment for a rare, fatal childhood disease
** Abeona Therapeutics ABEO.O out-licensed Fayuvi to Ultragenyx in 2022, granting the company global development and commercialization rights for the therapy
** ABEO shares up 3.5% premarket
** ABEO is eligible to receive certain commercial milestone payments and royalties tied to future product sales
** As of last close, RARE shares down ~37% YTD
(Reporting by Padmanabhan Ananthan)
Recent news on Ultragenyx Pharmaceutical
See all newsBrief: Ultragenyx Pharmaceutical Enters Settlement Agreement With Navinta On Dojolvi Patent Litigation - SEC Filing
Ultragenyx gains on $210 million US FDA voucher sale
Brief: Ultragenyx Pharmaceutical - Under Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih
Brief: Ultragenyx Enters Into Agreement To Sell Rare Pediatric Disease Priority Review Voucher For $210 Million
U.S. STOCKS ON THE MOVE-CoreWeave, StubHub, Ultragenyx